This tool will take you through current, open clinical trials in the UK and help you to understand which trials may be suitable for you. With any clinical trial you will need to be referred by your Health Care Specialist, always seek advice when considering clinical trials.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332
The Myeloma Trial Finder is intended only to provide information about clinical trials currently available in the UK. Trials included on Myeloma Trial Finder are not necessarily endorsed by Myeloma UK. Clinical trials involve inherent risks and any decision to participate, or not participate, in a clinical trial should be taken only after a careful assessment of the risks involved in it. Please speak to your haematologist if you are interested in taking part in a clinical trial. To the fullest extent permitted by law Myeloma UK excludes all liability howsoever arising (including negligence) as a consequence of, or in connection with, the use of information provided by Myeloma Trial Finder
There are currently 28 open trials.
In 123 locations
What is a Clinical Trial?
There are currently 28 open trials
- Phase 1 Trial of CXD101 in Patients With Advanced Cancer
- MGUS research study
- AZD4573 in relapsed or refractory myeloma
- Daratumumab vs. monitoring in high risk smouldering myeloma
- Selinexor for relapsed and refractory myeloma (BOSTON)
- RO6870810 monotherapy and combination for relapsed and refractory myeloma patients
- Subcutaneous vs. intravenous daratumumab in relapsed and/or refractory myeloma
- Ixazomib, pomalidomide and dexamethasone for relapsed and/or refractory myeloma patients
- Targeted radiotherapy for myeloma
- Pre-transplant exercise for myeloma patients (PREeMPT)
- Observational study of presentation, treatment and outcomes in myeloma patients (INSIGHT-MM)
- Observational evaluation of myeloma patients (PREAMBLE)
- Image guided theranostics in myeloma (iTIMM)
- Acupuncture for chemotherapy induced peripheral neuropathy in myeloma (ACUFOCIN)
- Ixazomib maintenance treatment for newly diagnosed myeloma patients
- MUK nine b: OPTIMUM
- CAR-T cell therapy for relapsed and/or refractory myeloma (APRIL)
- Melflufen and dexamethasone in myleoma patients refractory to lenalidomide (OCEAN trial)
- TAS-120 for refractory myeloma patients with FGF/FGFR abnormalities
- CC-220 monotherapy and combination for relapsed and refractory myeloma patients
- MUK eleven (Reolysin trial)
- Myeloma XII (ACCoRd)
- Ixazomib and dexamethasone for relapsed or refractory AL amyloidosis patients
- MUK eight
- Carfilzomib for newly diagnosed patients prior to stem cell transplant (CARDAMON trial)
- Bendamustine combination for newly diagnosed myeloma patients with kidney impairment (OPTIMAL trial)
- GSK2857916 trial
- GSK525762 trial
Trial Title:
Phase 1 Trial of CXD101 in Patients With Advanced Cancer
Treatments:
CXD101
Myeloma stage:
Relapsed, Refractory, Newly Diagnosed, High risk myeloma
Trial phase:
I
Summary:
The purpose of this study is to determine the highest dose of CXD101 (a novel histone deacetylase inhibitor) that can be safely administered to patients with advanced tumours. The study will also investigate the use of HR23B expression in tumour as a biomarker of response to treatment with CXD101.
Locations:
Oxford University Hospital, Oxford
Who can enter the study?:
Patients with solid tumours, lymphoma and myeloma can be considered for this study.
What's involved?:
Patients will be treated with CXD101 administered orally starting at 1mg twice a day (ie: 2mg/day). Dose escalation will proceed according to a standard 3+3 phase 1 scheme. Adverse experiences will be evaluated according to the NCI Common Terminology Criteria for Adverse Events, version 4.0. Dose escalation will continue until dose limiting toxicity is encountered in >1/3rd of patients at any dose level. The dose level below this will be determined to be the maximum tolerated dose. Patients will be treated, at the discretion of the Principal Investigator, until disease progression, unacceptable toxicity or the withdrawal of consent. At the maximum tolerated dose a further 20 patients, defined by tumour HR23B expression will be enrolled.
Clinical Information
(for Medical Professionals):
Dose escalation study of CXD101 administered orally twice daily for 5 consecutive days in every 21 day cycle. Starting dose 1mg twice daily (2mg/day).
For more information, click here
Find out more: